Doxorubicin



Indications and Reactions:

Role Indications Reactions
Primary
Acute Lymphocytic Leukaemia 15.0%
Diffuse Large B-cell Lymphoma 10.1%
Breast Cancer 8.8%
B-cell Lymphoma 8.3%
Mantle Cell Lymphoma 6.2%
Hodgkin's Disease 6.1%
Plasma Cell Myeloma 6.1%
Bone Sarcoma 5.0%
Non-hodgkin's Lymphoma 4.5%
Ewing's Sarcoma 4.2%
Prophylaxis 4.1%
Product Used For Unknown Indication 4.0%
Neuroblastoma 3.1%
Burkitt's Lymphoma 2.5%
Peripheral T-cell Lymphoma Unspecified 2.4%
Sarcoma 2.1%
T-cell Lymphoma 2.0%
Premedication 1.9%
Lymphoma 1.7%
Prophylaxis Of Nausea And Vomiting 1.7%
Off Label Use 29.7%
Vomiting 10.1%
Thrombocytopenia 6.7%
Toxicity To Various Agents 6.7%
Sepsis 5.9%
Neutropenia 4.9%
Myelodysplastic Syndrome 4.4%
Death 4.0%
Pneumonia 3.2%
Wrong Technique In Drug Usage Process 3.2%
Traumatic Lung Injury 2.9%
Febrile Neutropenia 2.5%
Infection 2.3%
Hepatitis B 2.1%
Renal Failure 2.1%
Respiratory Failure 2.1%
Neuropathy Peripheral 1.9%
Pancytopenia 1.9%
Pyrexia 1.9%
Cardiotoxicity 1.7%
Secondary
Diffuse Large B-cell Lymphoma 21.4%
Product Used For Unknown Indication 10.5%
Acute Lymphocytic Leukaemia 10.0%
Breast Cancer 8.5%
B-cell Lymphoma 6.8%
Non-hodgkin's Lymphoma 5.9%
Hodgkin's Disease 5.0%
Prophylaxis 3.9%
Chromosome Analysis Abnormal 3.7%
Lymphoma 3.2%
Mantle Cell Lymphoma 3.1%
Sarcoma 2.8%
Drug Use For Unknown Indication 2.5%
Peripheral T-cell Lymphoma Unspecified 2.2%
Plasma Cell Myeloma 2.1%
Ewing's Sarcoma 2.1%
Burkitt's Lymphoma 1.8%
Neoplasm Malignant 1.6%
Prophylaxis Of Nausea And Vomiting 1.5%
Bone Sarcoma 1.4%
Death 10.8%
Febrile Neutropenia 9.6%
Drug Exposure During Pregnancy 7.1%
Thrombocytopenia 7.1%
Vomiting 6.4%
Off Label Use 6.1%
Neutropenia 5.0%
Sepsis 4.8%
Pneumonia 4.7%
Myelodysplastic Syndrome 4.3%
Infection 4.1%
Pyrexia 4.1%
Disease Progression 3.7%
Neutropenic Infection 3.7%
Toxicity To Various Agents 3.7%
Pulmonary Embolism 3.7%
White Blood Cell Count Decreased 3.7%
Malaise 2.9%
Mucosal Inflammation 2.3%
Venous Thrombosis 2.2%
Concomitant
Non-hodgkin's Lymphoma 15.0%
Product Used For Unknown Indication 11.4%
Diffuse Large B-cell Lymphoma 10.1%
B-cell Lymphoma 8.7%
Breast Cancer 7.1%
Drug Use For Unknown Indication 6.3%
Lymphoma 5.5%
Multiple Myeloma 4.4%
Chemotherapy 3.8%
Acute Lymphocytic Leukaemia 3.7%
Plasma Cell Myeloma 3.4%
Chronic Lymphocytic Leukaemia 3.4%
Breast Cancer Metastatic 3.3%
Non-hodgkin's Lymphoma Unspecified Histology Aggressive 2.8%
Prophylaxis 2.7%
Mantle Cell Lymphoma 2.1%
Prophylaxis Of Nausea And Vomiting 1.8%
T-cell Lymphoma 1.7%
Hodgkin's Disease 1.5%
Burkitt's Lymphoma 1.2%
Death 12.9%
Disease Progression 8.6%
Thrombocytopenia 7.9%
Vomiting 7.6%
Sepsis 6.3%
No Adverse Event 6.0%
Weight Decreased 5.6%
Febrile Neutropenia 5.3%
Toxicity To Various Agents 5.0%
Neutropenia 4.0%
White Blood Cell Count Decreased 4.0%
Pulmonary Embolism 3.6%
Drug Ineffective 3.3%
Progressive Multifocal Leukoencephalopathy 3.3%
Somnolence 3.3%
Encephalopathy 3.0%
Renal Failure Acute 2.6%
Respiratory Failure 2.6%
Thrombosis 2.6%
Acute Myeloid Leukaemia 2.3%
Interacting
Non-hodgkin's Lymphoma Unspecified Histology Aggressive 51.4%
Ewing's Sarcoma 22.9%
Oral Candidiasis 11.4%
Breast Cancer Metastatic 5.7%
Prophylaxis Of Nausea And Vomiting 5.7%
Prophylaxis 2.9%
Neuropathy Peripheral 28.6%
Renal Impairment 28.6%
Leukopenia 14.3%
Neutropenia 14.3%
Vomiting 14.3%